Propargylamine-derived multitarget-directed ligands: fighting Alzheimer's disease with monoamine oxidase inhibitors (Q38067297)

28 August 2017

1 reference

title

Propargylamine-derived multitarget-directed ligands: fighting Alzheimer's disease with monoamine oxidase inhibitors (English)

1 reference

28 August 2017

0 references

Alejandro Gella

2

0 references

Irene Bolea

object named as

Irene Bolea

series ordinal

1

0 references

Mercedes Unzeta

object named as

Mercedes Unzeta

series ordinal

3

0 references

publication date

13 December 2012

1 reference

Journal of Neural Transmission

28 August 2017

published in

1 reference

28 August 2017

volume

120

1 reference

28 August 2017

issue

6

1 reference

28 August 2017

page(s)

893-902

1 reference

Combination treatment in Alzheimer's disease: results of a randomized, controlled trial with cerebrolysin and donepezil.

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Alzheimer's disease--input of vitamin D with mEmantine assay (AD-IDEA trial): study protocol for a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Biogenic amines and their metabolites in Alzheimer's disease: noradrenaline, 5-hydroxytryptamine and 5-hydroxyindole-3-acetic acid depleted in hippocampus but not in substantia innominata.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Neuropsychiatric symptoms in dementia: importance and treatment considerations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

The cholinergic hypothesis of geriatric memory dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Lights and shadows on monoamine oxidase inhibition in neuroprotective pharmacological therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Memoquin: a multi-target-directed ligand as an innovative therapeutic opportunity for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: role in neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Depression and Alzheimer's disease: neurobiological links and common pharmacological targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Multi-target-directed ligands to combat neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Additive effects of a cholinesterase inhibitor and a histamine inverse agonist on scopolamine deficits in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Oxidative stress, glutamate, and neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Serotonin in Alzheimer-type dementia and other dementing illnesses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Neuroprotective effect of the monoamine oxidase inhibitor PF 9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine] on rat nigral neurons after 6-hydroxydopamine-striatal lesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Selective loss of central cholinergic neurons in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Amyloid-beta-Acetylcholinesterase complexes potentiate neurodegenerative changes induced by the Abeta peptide. Implications for the pathogenesis of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

First gallamine-tacrine hybrid: design and characterization at cholinesterases and the M2 muscarinic receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Synthesis and biological evaluation of NO-donor-tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Oxidative stress in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Amyloidosis of the nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Redox-active metals, oxidative stress, and Alzheimer's disease pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Some observations upon a new inhibitor of monoamine oxidase in brain tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Metal-catalyzed disruption of membrane protein and lipid signaling in the pathogenesis of neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Biochemical and molecular studies of NMDA receptor subunits NR1/2A/2B in hippocampal subregions throughout progression of Alzheimer's disease pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Combination therapy for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

PF 9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine], a new MAO-B inhibitor, attenuates MPTP-induced depletion of striatal dopamine levels in C57/BL6 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Protective effect of N-(2-propynyl)-2-(5-benzyloxyindolyl) methylamine (PF 9601N), a novel MAO-B inhibitor, on dopamine-lesioned PC12 cultured cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Necropsy evidence of central cholinergic deficits in senile dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

How important is oxidative damage? Lessons from Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

The novel type B MAO inhibitor PF9601N enhances the duration of L-DOPA-induced contralateral turning in 6-hydroxydopamine lesioned rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Increased neurofibrillary tangles in patients with Alzheimer disease with comorbid depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Monoamine oxidase-B inhibition in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Design and synthesis of N-benzylpiperidine-purine derivatives as new dual inhibitors of acetyl- and butyrylcholinesterase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Anti-apoptotic effect of Mao-B inhibitor PF9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine] is mediated by p53 pathway inhibition in MPP+-treated SH-SY5Y human dopaminergic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

PF9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine] confers MAO-B independent neuroprotection in ER stress-induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Biphasic and region-specific MAO-B response to aging in normal human brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

The Alzheimer's disease mitochondrial cascade hypothesis: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Monoamine oxidase-B inhibitors in the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Monoamine oxidases: certainties and uncertainties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Synergistic effects of selegiline and donepezil on cognitive impairment induced by amyloid beta (25-35).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Novel huprine derivatives with inhibitory activity toward β-amyloid aggregation and formation as disease-modifying anti-Alzheimer drug candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

The economic impact of dementia in Europe in 2008-cost estimates from the Eurocode project.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

New insights on how metals disrupt amyloid beta-aggregation and their effects on amyloid-beta cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

CNS Targets for multi-functional drugs in the treatment of Alzheimer's and Parkinson's diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate].

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Site-activated multifunctional chelator with acetylcholinesterase and neuroprotective-neurorestorative moieties for Alzheimer's therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Site-activated chelators targeting acetylcholinesterase and monoamine oxidase for Alzheimer's therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0948-Y

Relation of the tocopherol forms to incident Alzheimer disease and to cognitive change

21 January 2018

1 reference

12 December 2020

CYP-dependent metabolism of PF9601N, a new monoamine oxidase-B inhibitor, by C57BL/6 mouse and human liver microsomes.

1 reference

12 December 2020

The new generation of monoamine oxidase inhibitors

1 reference

12 December 2020

A structural motif of acetylcholinesterase that promotes amyloid beta-peptide fibril formation

1 reference

12 December 2020

The frequency of cognitive impairment in patients with anxiety, depression, and bipolar disorder: an unaccounted source of variance in clinical trials.

1 reference

12 December 2020

Involvement of multiple survival signal transduction pathways in the neuroprotective, neurorescue and APP processing activity of rasagiline and its propargyl moiety

1 reference

12 December 2020

Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine

1 reference

12 December 2020

Iron involvement in neural damage and microgliosis in models of neurodegenerative diseases

1 reference

12 December 2020

ULTRASTRUCTURAL STUDIES IN ALZHEIMER'S PRESENILE DEMENTIA

1 reference

12 December 2020

Neuroprotection by propargylamines in Parkinson's disease: intracellular mechanism underlying the anti-apoptotic function and search for clinical markers

1 reference

12 December 2020

Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat

1 reference

12 December 2020

Involvement of MAP kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline

1 reference

12 December 2020

Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies

1 reference

12 December 2020

Multiple central nervous system targets for eliciting beneficial effects on memory and cognition.

1 reference

12 December 2020

Protective effect of N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine (PF9601N) on mitochondrial permeability transition

1 reference

12 December 2020

Antiapoptotic properties of rasagiline, N-propargylamine-1(R)-aminoindan, and its optical (S)-isomer, TV1022.

1 reference

12 December 2020

Galantamine for Alzheimer's disease

1 reference

12 December 2020

Extrapyramidal symptoms and signs in Alzheimer's disease: prevalence and correlation with the first symptom

1 reference

12 December 2020

Drug interactions with reversible monoamine oxidase-A inhibitors.

1 reference

12 December 2020

Donepezil for dementia due to Alzheimer's disease

1 reference

12 December 2020

Memantine for dementia

1 reference

12 December 2020

Rivastigmine for Alzheimer's disease.

1 reference

12 December 2020

10.1007/S00702-012-0948-Y

Identifiers

DOI

1 reference

28 August 2017

1 reference